National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

aprepitantPatient Information
A small molecule, high-affinity substance P antagonist (SPA) with antiemetic activity. Crossing the blood brain barrier, aprepitant binds selectively to the human substance P/neurokinin 1 receptor in the central nervous system (CNS), thereby inhibiting receptor binding of endogenous substance P and substance P-induced emesis. This agent has little or no affinity for serotonin type 3 (5-HT3), dopamine, and corticosteroid receptors. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

US brand name:Emend
Code names:L-754030
MK-0869
ONO-7436



Previous:apoptosis inducer BZL101, apoptosis inducer GCS-100, apoptosis inducer GMX1777, apoptosis inducer MPC-2130, APOTONE
Next:apricoxib, aprotinin bovine, Aptosyn, Aquadiol, Aquaphor

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov